Notification of Preliminary Results

RNS Number : 6451W

Alliance Pharma PLC

02 February 2012

 



For immediate release

2 February 2012

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Preliminary Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its preliminary results for the year ended 31 December 2011 on Thursday 22 March 2012.

A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan Communications, 107 Cheapside, London EC2V 6DN.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications	+ 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections.  Alliance's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

NORLLFSDFFILIIF